In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
M Sobrinho-Simoes, V Wilczek, J Score… - Blood, The Journal …, 2010 - ashpublications.org
It is not clear if absence of BCR-ABL transcripts—complete molecular response (CMR)—is
synonymous with, or required for, cure of chronic myeloid leukemia (CML). Some patients …
synonymous with, or required for, cure of chronic myeloid leukemia (CML). Some patients …
Instability of BCR–ABL gene in primary and cultured chronic myeloid leukemia stem cells
X Jiang, KM Saw, A Eaves… - Journal of the National …, 2007 - academic.oup.com
Background Imatinib mesylate treatment causes remissions in a majority of patients with
chronic myeloid leukemia (CML), but relapses are an increasing problem. We hypothesized …
chronic myeloid leukemia (CML), but relapses are an increasing problem. We hypothesized …
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA …
Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
DJ Barnes, D Palaiologou, E Panousopoulou… - Cancer research, 2005 - AACR
Chronic myeloid leukemia (CML) starts with the acquisition of a BCR-ABL fusion gene in a
single hematopoietic stem cell, but the time to progression is unpredictable. Although the …
single hematopoietic stem cell, but the time to progression is unpredictable. Although the …
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients
S Hayette, M Michallet, ML Baille, JP Magaud… - Leukemia research, 2005 - Elsevier
Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL+ cells during
the follow-up of CML could be useful for optimizing therapeutic management. We …
the follow-up of CML could be useful for optimizing therapeutic management. We …
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
A Kumari, C Brendel, A Hochhaus… - Blood, The Journal …, 2012 - ashpublications.org
BCR-ABL overexpression and stem cell quiescence supposedly contribute to the failure of
imatinib mesylate (IM) to eradicate chronic myeloid leukemia (CML). However, BCR-ABL …
imatinib mesylate (IM) to eradicate chronic myeloid leukemia (CML). However, BCR-ABL …
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
MC Müller, N Gattermann, T Lahaye, MWN Deininger… - Leukemia, 2003 - nature.com
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
No evidence for persistence of BCR-ABL–positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia
M Deininger, T Lehmann, R Krahl… - Blood, The Journal …, 2000 - ashpublications.org
Blood ASH 96/2 treatment with BMT, and serial samples were analyzed for levels of
genomic and mRNA BCR-ABL using DNA-PCR with patientspecific primers and RT-PCR …
genomic and mRNA BCR-ABL using DNA-PCR with patientspecific primers and RT-PCR …
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic …
RD Press, C Galderisi, R Yang, C Rempfer… - Clinical Cancer …, 2007 - AACR
Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …